

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**三生制药**  
**3SBIO INC.**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1530)**

**(Convertible Bonds Codes: 5241 and 40285)**

## **COMPLETION OF THE SPIN-OFF AND SEPARATE LISTING OF SUNSHINE GUOJIAN ON THE STAR MARKET**

References are made to the announcements of the Company dated 9 July 2020, 24 June 2020 and 31 October 2019 (the “**Announcements**”), as well as the Company’s annual report dated 29 April 2020, in relation to the Proposed Spin-off and Proposed A Share Listing. Unless otherwise defined, terms used in this announcement shall have the same meaning in the Announcements.

The Board is pleased to announce that (i) the Proposed Listing on the STAR Market and the Offering have been completed; and (ii) the dealings in the ordinary shares of Sunshine Guojian on the STAR Market commenced on 22 July 2020.

By order of the Board  
**3SBio Inc.**  
**Dr. LOU Jing**  
*Chairman*

Shenyang, the PRC  
22 July 2020

*As at the date of this announcement, the directors of the Company are Dr. LOU Jing and Ms. SU Dongmei as executive directors; Mr. HUANG Bin and Mr. TANG Ke as non-executive directors; and Mr. PU Tianruo, Mr. David Ross PARKINSON and Dr. WONG Lap Yan as independent non-executive directors.*